Company News: GlaxoSmithKline and Nabi

Share this article:
GlaxoSmithKline acquired exclusive worldwide rights to in-license a nicotine-addiction vaccine developed by Nabi and to use the biotech firm's technology to develop its own vaccines. GSK will pay Nabi a $40-million upfront for the option of in-licensing NicVAX following completion of phase III testing. Nabi can receive as much as $500 million in option fees and regulatory, development and sales milestones for NicVAX, as well as from any second-generation GSK nicotine vaccines. Should GSK exercise its option, Nabi is also entitled to receive double-digit royalties on global sales of NicVAX and any follow-on products. The deal is expected to close in first quarter 2010.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.